Clin Oncol | Volume 4, Issue 1 | Case Report | Open Access

Case Report of Pathologically Confirmed Complete Response of Metastatic Breast Cancer after Long Term Experimental Antiangiogenic Treatment as Addition to Standard Therapeutic Approach

Mariani G1*, Galli G1, Marchianò A2 , Regalia E3 , Gianni L4 and Valagussa P5

1Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy 2Department of Radiology, Fondazione IRCCS Istituto Nazionale Tumori, Italy 3Fondazione IRCCS Istituto Nazionale Tumori, Italy 4Department of Medical Oncology, San Raffaele Hospital Scientific Institute, Italy 5Fondazione Michelangelo, Italy

*Correspondance to: Mariani Gabriella 

Fulltext PDF

Abstract

Metastatic breast cancer otherwise called stage IV or advanced breast cancer is one among the unspecific types of cancer and is most advanced. It spreads to lymph nodes and to other organs but still considered as breast cancer. Metastatic Breast Cancer (MBC) has remained an incurable disease so Complete Response (CR) in MBC is rare. However survival rates of patients with Metastatic Breast Cancer has gradually prolonged over the past few years due to improvement of Antineoplastic agents.

Keywords:

Metastatic breast cancer; Antiangiogenic treatment; Sorafenib

Citation:

Mariani G, Galli G, Marchianò A, Regalia E, Gianni L, Valagussa P. GTV Cochlea Distance to Predict the Case Report of Pathologically Confirmed Complete Response of Metastatic Breast Cancer after Long Term Experimental Antiangiogenic Treatment as Addition to Standard Therapeutic Approach. Clin Oncol. 2019;4:1666.

Subscribe to Our Newsletter